Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ANGIO-A: Safety and Tolerability of Oral Cyclophosphamide and Sorafenib With Intravenous Bevacizumab With the Addition of Atezolizumab in Pediatric Solid Tumor Patients

Next Previous
X
Search
Trial Profile

ANGIO-A: Safety and Tolerability of Oral Cyclophosphamide and Sorafenib With Intravenous Bevacizumab With the Addition of Atezolizumab in Pediatric Solid Tumor Patients

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cyclophosphamide (Primary) ; Sorafenib (Primary)
  • Indications Liver cancer; Solid tumours
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Acronyms ANGIO-A

    • Most Recent Events

    • 29 Mar 2024 Results determining if SOR systemic exposure can be targeted to an AUC by day 21 of course 1 in 60 percent of patients when given in combination with CTX, BEV, and ATZ, presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 04 Aug 2022 Planned initiation date changed from 1 Jul 2022 to 1 Sep 2022.
    • 04 Aug 2022 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jul 2022 to 1 Sep 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top